Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deffered Revenue: 2023-2025

Historic Non-Current Deffered Revenue for BridgeBio Pharma (BBIO) over the last 2 years, with Sep 2025 value amounting to $13.1 million.

  • BridgeBio Pharma's Non-Current Deffered Revenue fell 29.51% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 29.51%. This contributed to the annual value of $17.1 million for FY2024, which is 358.68% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Non-Current Deffered Revenue stood at $13.1 million, which was down 10.47% from $14.7 million recorded in Q2 2025.
  • BridgeBio Pharma's Non-Current Deffered Revenue's 5-year high stood at $19.9 million during Q1 2024, with a 5-year trough of $3.7 million in Q4 2023.
  • For the 3-year period, BridgeBio Pharma's Non-Current Deffered Revenue averaged around $15.2 million, with its median value being $17.0 million (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Non-Current Deffered Revenue skyrocketed by 358.68% in 2024, and later decreased by 29.51% in 2025.
  • BridgeBio Pharma's Non-Current Deffered Revenue (Quarterly) stood at $3.7 million in 2023, then skyrocketed by 358.68% to $17.1 million in 2024, then declined by 29.51% to $13.1 million in 2025.
  • Its Non-Current Deffered Revenue was $13.1 million in Q3 2025, compared to $14.7 million in Q2 2025 and $17.5 million in Q1 2025.